Objective: This study aims to investigate the relationship of monocyte to high-density lipoprotein cholesterol ratio (MHR) with diabetes mellitus (DM) and diabetic nephropathy.
Methods: This study included 262 Type-2 diabetes mellitus patients, of which 60 had diabetic nephropathy and 202 did not have diabetic nephropathy who presented to the internal diseases polyclinic at Firat University Medical Faculty Hospital between May 2018 and October 2018 and 50 healthy control subjects. A retrospective scan of patient files was conducted and information relevant to nephropathy such as hemoglobin, glycated hemoglobin levels (HbA1c), hematocrit count (HCT), monocyte count, LDL, HDL, triglyceride levels, and microvascular complications were acquired.
Results: We determined MHR values as 11.9±5.5 and 8.4±2.9 respectively for the diabetic and healthy groups. There was a statistically significant difference between the two groups in terms of MHR, with a positive correlation between diabetes and MHR (< 0.001; r: 0.241). Moreover, glucose, HDL, and triglyceride levels were different between the two groups with statistical significance (respectively, p< 0.001; p< 0.001; p< 0.001). Our study found higher MHR levels for patients with diabetic nephropathy compared to those without diabetic nephropathy (respectively, 17.1±7.9 and 10.3±3.3) and determined statistical significance and a negative correlation (p< 0.001; r: -0.512).
Conclusion: Our results suggest that an elevated MHR can be a biomarker for diabetic nephropathy, allowing the detection of diabetic nephropathy with simple and inexpensive laboratory tests.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659096 | PMC |
http://dx.doi.org/10.12669/pjms.35.4.534 | DOI Listing |
J Res Med Sci
November 2024
Water and Electrolytes Research Center, and Department of Physiology, Isfahan University of Medical Sciences, Isfahan, Iran.
PLoS One
January 2025
Department of Nephrology, Pu'er People's Hospital, Pu'er, Yunnan, China.
Diabetic nephropathy (DN) is the single largest cause of end-stage renal disease (ESRD). Inflammation reaction mediated by NLRP3 inflammasome and Nrf2-related oxidative stress have been considered to play a very important role in the progress of diabetic nephropathy (DN). Effective drugs for the treatment of diabetic nephropathy still need to be explored.
View Article and Find Full Text PDFCureus
December 2024
Internal Medicine, Kempegowda Institute of Medical Sciences, Bengaluru, IND.
Background Type 2 diabetes mellitus (T2DM) is associated with a high risk of developing microvascular complications such as diabetic nephropathy, diabetic neuropathy (DN), and diabetic retinopathy (DR), leading to significant morbidity. Early detection of these complications is crucial for improving patient outcomes. Neutrophil-lymphocyte ratio (NLR) and urine albumin-creatinine ratio (UACR) show promise as cost-effective and accessible biomarkers for the early detection of microvascular complications in T2DM.
View Article and Find Full Text PDFHeliyon
January 2025
Department of Nephrology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Long noncoding RNAs may function as competitive endogenous RNAs by sponging microRNAs, thereby contributing to the progression of diabetic nephropathy. In this study, a potential diabetic nephropathy-related long noncoding-microRNA-mRNA axis, Gm4419-miR-455-3p-, was predicted using bioinformatics methods. To verify the role of the Gm4419-miR-455-3p- axis in diabetic nephropathy, an high glucose-induced mesangial cell model was established.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
January 2025
Department of Nephrology, Affiliated Bao'an Hospital of Shenzhen, The Second School of Clinical Medicine, Southern Medical University, Shenzhen, China.
Objectives: The study will evaluate the effectiveness and safety of finerenone in patients diagnosed with diabetic kidney disease (DKD).
Methods: Various databases including PubMed, Sinomed, Web of Science, Embase, Clinical Trials, and Cochrane Library were systematically reviewed for pertinent studies published from the beginning to February 2024.This meta-analysis utilized RevMan 5.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!